Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Understanding TCR affinity, antigen specificity, and cross-reactivity to improve TCR gene-modified T cells for cancer immunotherapy.

Spear TT, Evavold BD, Baker BM, Nishimura MI.

Cancer Immunol Immunother. 2019 Oct 8. doi: 10.1007/s00262-019-02401-0. [Epub ahead of print] Review.

PMID:
31595324
2.

Discriminative T cell recognition of cross-reactive islet-antigens is associated with HLA-DQ8 transdimer-mediated autoimmune diabetes.

Chow IT, Gates TJ, Papadopoulos GK, Moustakas AK, Kolawole EM, Notturno RJ, McGinty JW, Torres-Chinn N, James EA, Greenbaum C, Nepom GT, Evavold BD, Kwok WW.

Sci Adv. 2019 Aug 21;5(8):eaaw9336. doi: 10.1126/sciadv.aaw9336. eCollection 2019 Aug.

3.

PD-1 Dynamically Regulates Inflammation and Development of Brain-Resident Memory CD8 T Cells During Persistent Viral Encephalitis.

Shwetank, Frost EL, Mockus TE, Ren HM, Toprak M, Lauver MD, Netherby-Winslow CS, Jin G, Cosby JM, Evavold BD, Lukacher AE.

Front Immunol. 2019 Apr 17;10:783. doi: 10.3389/fimmu.2019.00783. eCollection 2019.

4.

Mechano-regulation of Peptide-MHC Class I Conformations Determines TCR Antigen Recognition.

Wu P, Zhang T, Liu B, Fei P, Cui L, Qin R, Zhu H, Yao D, Martinez RJ, Hu W, An C, Zhang Y, Liu J, Shi J, Fan J, Yin W, Sun J, Zhou C, Zeng X, Xu C, Wang J, Evavold BD, Zhu C, Chen W, Lou J.

Mol Cell. 2019 Mar 7;73(5):1015-1027.e7. doi: 10.1016/j.molcel.2018.12.018. Epub 2019 Jan 30.

PMID:
30711376
5.

A TCR mechanotransduction signaling loop induces negative selection in the thymus.

Hong J, Ge C, Jothikumar P, Yuan Z, Liu B, Bai K, Li K, Rittase W, Shinzawa M, Zhang Y, Palin A, Love P, Yu X, Salaita K, Evavold BD, Singer A, Zhu C.

Nat Immunol. 2018 Dec;19(12):1379-1390. doi: 10.1038/s41590-018-0259-z. Epub 2018 Nov 12.

6.

2D Kinetic Analysis of TCR and CD8 Coreceptor for LCMV GP33 Epitopes.

Kolawole EM, Andargachew R, Liu B, Jacobs JR, Evavold BD.

Front Immunol. 2018 Oct 15;9:2348. doi: 10.3389/fimmu.2018.02348. eCollection 2018.

7.

Differential IL-2 expression defines developmental fates of follicular versus nonfollicular helper T cells.

DiToro D, Winstead CJ, Pham D, Witte S, Andargachew R, Singer JR, Wilson CG, Zindl CL, Luther RJ, Silberger DJ, Weaver BT, Kolawole EM, Martinez RJ, Turner H, Hatton RD, Moon JJ, Way SS, Evavold BD, Weaver CT.

Science. 2018 Sep 14;361(6407). pii: eaao2933. doi: 10.1126/science.aao2933.

8.

Isolation of a Structural Mechanism for Uncoupling T Cell Receptor Signaling from Peptide-MHC Binding.

Sibener LV, Fernandes RA, Kolawole EM, Carbone CB, Liu F, McAffee D, Birnbaum ME, Yang X, Su LF, Yu W, Dong S, Gee MH, Jude KM, Davis MM, Groves JT, Goddard WA 3rd, Heath JR, Evavold BD, Vale RD, Garcia KC.

Cell. 2018 Jul 26;174(3):672-687.e27. doi: 10.1016/j.cell.2018.06.017.

9.

T Cell Receptor-Major Histocompatibility Complex Interaction Strength Defines Trafficking and CD103+ Memory Status of CD8 T Cells in the Brain.

Sanecka A, Yoshida N, Kolawole EM, Patel H, Evavold BD, Frickel EM.

Front Immunol. 2018 Jun 5;9:1290. doi: 10.3389/fimmu.2018.01290. eCollection 2018.

10.

CD4 T Cell Affinity Diversity Is Equally Maintained during Acute and Chronic Infection.

Andargachew R, Martinez RJ, Kolawole EM, Evavold BD.

J Immunol. 2018 Jul 1;201(1):19-30. doi: 10.4049/jimmunol.1800295. Epub 2018 May 18.

11.

Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.

Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, Dellacecca E, Garrett-Mayer E, Li M, Eby JM, Stiff PJ, Evavold BD, Baker BM, Le Poole IC, Dropulic B, Clark JI, Nishimura MI.

Cancer Immunol Immunother. 2018 Feb;67(2):327. doi: 10.1007/s00262-017-2102-z.

PMID:
29264697
12.

Dual Molecular Mechanisms Govern Escape at Immunodominant HLA A2-Restricted HIV Epitope.

Cole DK, Fuller A, Dolton G, Zervoudi E, Legut M, Miles K, Blanchfield L, Madura F, Holland CJ, Bulek AM, Bridgeman JS, Miles JJ, Schauenburg AJA, Beck K, Evavold BD, Rizkallah PJ, Sewell AK.

Front Immunol. 2017 Nov 10;8:1503. doi: 10.3389/fimmu.2017.01503. eCollection 2017.

13.

Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.

Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, Dellacecca E, Garrett-Mayer E, Li M, Eby JM, Stiff PJ, Evavold BD, Baker BM, Le Poole IC, Dropulic B, Clark JI, Nishimura MI.

Cancer Immunol Immunother. 2018 Feb;67(2):311-325. doi: 10.1007/s00262-017-2073-0. Epub 2017 Oct 20. Erratum in: Cancer Immunol Immunother. 2017 Dec 20;:.

14.

NFM Cross-Reactivity to MOG Does Not Expand a Critical Threshold Level of High-Affinity T Cells Necessary for Onset of Demyelinating Disease.

Blanchfield L, Sabatino JJ Jr, Lawrence L, Evavold BD.

J Immunol. 2017 Oct 15;199(8):2680-2691. doi: 10.4049/jimmunol.1700792. Epub 2017 Sep 8.

15.

Low-affinity CD4+ T cells are major responders in the primary immune response.

Martinez RJ, Andargachew R, Martinez HA, Evavold BD.

Nat Commun. 2016 Dec 15;7:13848. doi: 10.1038/ncomms13848.

16.

MHC Bias by T Cell Receptors: Genetic Evidence for MHC and TCR Coevolution.

Baker BM, Evavold BD.

Trends Immunol. 2017 Jan;38(1):2-4. doi: 10.1016/j.it.2016.11.003. Epub 2016 Dec 9.

17.

Conserved Region C Functions To Regulate PD-1 Expression and Subsequent CD8 T Cell Memory.

Bally AP, Tang Y, Lee JT, Barwick BG, Martinez R, Evavold BD, Boss JM.

J Immunol. 2017 Jan 1;198(1):205-217. Epub 2016 Nov 28.

18.

Targeted loss of SHP1 in murine thymocytes dampens TCR signaling late in selection.

Martinez RJ, Morris AB, Neeld DK, Evavold BD.

Eur J Immunol. 2016 Sep;46(9):2103-10. doi: 10.1002/eji.201646475.

19.

Ratiometric Tension Probes for Mapping Receptor Forces and Clustering at Intermembrane Junctions.

Ma VP, Liu Y, Blanchfield L, Su H, Evavold BD, Salaita K.

Nano Lett. 2016 Jul 13;16(7):4552-9. doi: 10.1021/acs.nanolett.6b01817. Epub 2016 Jun 2.

20.

Viral Escape Mutant Epitope Maintains TCR Affinity for Antigen yet Curtails CD8 T Cell Responses.

Shorter SK, Schnell FJ, McMaster SR, Pinelli DF, Andargachew R, Evavold BD.

PLoS One. 2016 Feb 25;11(2):e0149582. doi: 10.1371/journal.pone.0149582. eCollection 2016.

21.

Low-Affinity Memory CD8+ T Cells Mediate Robust Heterologous Immunity.

Krummey SM, Martinez RJ, Andargachew R, Liu D, Wagener M, Kohlmeier JE, Evavold BD, Larsen CP, Ford ML.

J Immunol. 2016 Mar 15;196(6):2838-46. doi: 10.4049/jimmunol.1500639. Epub 2016 Feb 10.

22.

Lower Affinity T Cells are Critical Components and Active Participants of the Immune Response.

Martinez RJ, Evavold BD.

Front Immunol. 2015 Sep 10;6:468. doi: 10.3389/fimmu.2015.00468. eCollection 2015. Review.

23.

Regulatory and T Effector Cells Have Overlapping Low to High Ranges in TCR Affinities for Self during Demyelinating Disease.

Hood JD, Zarnitsyna VI, Zhu C, Evavold BD.

J Immunol. 2015 Nov 1;195(9):4162-70. doi: 10.4049/jimmunol.1501464. Epub 2015 Sep 18.

24.

Cutting Edge: Resident Memory CD8 T Cells Express High-Affinity TCRs.

Frost EL, Kersh AE, Evavold BD, Lukacher AE.

J Immunol. 2015 Oct 15;195(8):3520-4. doi: 10.4049/jimmunol.1501521. Epub 2015 Sep 14.

25.

Force-Regulated In Situ TCR-Peptide-Bound MHC Class II Kinetics Determine Functions of CD4+ T Cells.

Hong J, Persaud SP, Horvath S, Allen PM, Evavold BD, Zhu C.

J Immunol. 2015 Oct 15;195(8):3557-64. doi: 10.4049/jimmunol.1501407. Epub 2015 Sep 2.

26.

Identification of T cell clones without the need for sequencing.

Martinez RJ, Neeld DK, Evavold BD.

J Immunol Methods. 2015 Sep;424:28-31. doi: 10.1016/j.jim.2015.04.018. Epub 2015 May 8.

27.

Progression of relapsing-remitting demyelinating disease does not require increased TCR affinity or epitope spread.

Kersh AE, Edwards LJ, Evavold BD.

J Immunol. 2014 Nov 1;193(9):4429-38. doi: 10.4049/jimmunol.1401456. Epub 2014 Sep 29.

28.

TCR affinity and tolerance mechanisms converge to shape T cell diabetogenic potential.

Bettini M, Blanchfield L, Castellaw A, Zhang Q, Nakayama M, Smeltzer MP, Zhang H, Hogquist KA, Evavold BD, Vignali DA.

J Immunol. 2014 Jul 15;193(2):571-9. doi: 10.4049/jimmunol.1400043. Epub 2014 Jun 18.

29.

Accumulation of serial forces on TCR and CD8 frequently applied by agonist antigenic peptides embedded in MHC molecules triggers calcium in T cells.

Pryshchep S, Zarnitsyna VI, Hong J, Evavold BD, Zhu C.

J Immunol. 2014 Jul 1;193(1):68-76. doi: 10.4049/jimmunol.1303436. Epub 2014 Jun 2.

30.

Accumulation of dynamic catch bonds between TCR and agonist peptide-MHC triggers T cell signaling.

Liu B, Chen W, Evavold BD, Zhu C.

Cell. 2014 Apr 10;157(2):357-368. doi: 10.1016/j.cell.2014.02.053.

31.

Estimating the diversity, completeness, and cross-reactivity of the T cell repertoire.

Zarnitsyna VI, Evavold BD, Schoettle LN, Blattman JN, Antia R.

Front Immunol. 2013 Dec 26;4:485. doi: 10.3389/fimmu.2013.00485. Review.

32.

Destabilization of peptide:MHC interaction induces IL-2 resistant anergy in diabetogenic T cells.

Edwards LJ, Evavold BD.

J Autoimmun. 2013 Aug;44:82-90. doi: 10.1016/j.jaut.2013.07.002. Epub 2013 Jul 26.

33.

Monitoring the Dynamics of T Cell Clonal Diversity Using Recombinant Peptide:MHC Technology.

Blanchfield JL, Shorter SK, Evavold BD.

Front Immunol. 2013 Jul 3;4:170. doi: 10.3389/fimmu.2013.00170. eCollection 2013.

34.

Peptide immunization elicits polyomavirus-specific MHC class ib-restricted CD8 T cells in MHC class ia allogeneic mice.

Hofstetter AR, Evavold BD, Lukacher AE.

Viral Immunol. 2013 Feb;26(1):109-13. doi: 10.1089/vim.2012.0052. Epub 2013 Feb 1.

35.

Insights from in situ analysis of TCR-pMHC recognition: response of an interaction network.

Zhu C, Jiang N, Huang J, Zarnitsyna VI, Evavold BD.

Immunol Rev. 2013 Jan;251(1):49-64. doi: 10.1111/imr.12016. Review.

36.

Sustained Rap1 activation in autoantigen-specific T lymphocytes attenuates experimental autoimmune encephalomyelitis.

Salinas GF, Krausz S, Dontje W, Evavold BD, Tak PP, Baeten DL, Reedquist KA.

J Neuroimmunol. 2012 Sep 15;250(1-2):35-43. doi: 10.1016/j.jneuroim.2012.05.012. Epub 2012 Jun 10.

37.

Insights into T cell recognition of antigen: significance of two-dimensional kinetic parameters.

Edwards LJ, Zarnitsyna VI, Hood JD, Evavold BD, Zhu C.

Front Immunol. 2012 Apr 20;3:86. doi: 10.3389/fimmu.2012.00086. eCollection 2012.

38.

Low 2-dimensional CD4 T cell receptor affinity for myelin sets in motion delayed response kinetics.

Rosenthal KM, Edwards LJ, Sabatino JJ Jr, Hood JD, Wasserman HA, Zhu C, Evavold BD.

PLoS One. 2012;7(3):e32562. doi: 10.1371/journal.pone.0032562. Epub 2012 Mar 7.

39.

Self-reactive human CD4 T cell clones form unusual immunological synapses.

Schubert DA, Gordo S, Sabatino JJ Jr, Vardhana S, Gagnon E, Sethi DK, Seth NP, Choudhuri K, Reijonen H, Nepom GT, Evavold BD, Dustin ML, Wucherpfennig KW.

J Exp Med. 2012 Feb 13;209(2):335-52. doi: 10.1084/jem.20111485. Epub 2012 Feb 6.

40.

CIITA promoter I CARD-deficient mice express functional MHC class II genes in myeloid and lymphoid compartments.

Zinzow-Kramer WM, Long AB, Youngblood BA, Rosenthal KM, Butler R, Mohammed AU, Skountzou I, Ahmed R, Evavold BD, Boss JM.

Genes Immun. 2012 Jun;13(4):299-310. doi: 10.1038/gene.2011.86. Epub 2012 Jan 5.

41.

T cell recognition of weak ligands: roles of signaling, receptor number, and affinity.

Edwards LJ, Evavold BD.

Immunol Res. 2011 May;50(1):39-48. doi: 10.1007/s12026-011-8204-3. Review.

42.

Two-stage cooperative T cell receptor-peptide major histocompatibility complex-CD8 trimolecular interactions amplify antigen discrimination.

Jiang N, Huang J, Edwards LJ, Liu B, Zhang Y, Beal CD, Evavold BD, Zhu C.

Immunity. 2011 Jan 28;34(1):13-23. doi: 10.1016/j.immuni.2010.12.017. Epub 2011 Jan 20.

43.

High prevalence of low affinity peptide-MHC II tetramer-negative effectors during polyclonal CD4+ T cell responses.

Sabatino JJ Jr, Huang J, Zhu C, Evavold BD.

J Exp Med. 2011 Jan 17;208(1):81-90. doi: 10.1084/jem.20101574. Epub 2011 Jan 10.

44.
45.

The kinetics of two-dimensional TCR and pMHC interactions determine T-cell responsiveness.

Huang J, Zarnitsyna VI, Liu B, Edwards LJ, Jiang N, Evavold BD, Zhu C.

Nature. 2010 Apr 8;464(7290):932-6. doi: 10.1038/nature08944. Epub 2010 Mar 31.

46.

A unique unresponsive CD4+ T cell phenotype post TCR antagonism.

Edwards LJ, Evavold BD.

Cell Immunol. 2010;261(1):64-8. doi: 10.1016/j.cellimm.2009.11.002. Epub 2009 Dec 23.

47.

Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE.

Sabatino JJ Jr, Rosenthal KM, Evavold BD.

J Neuroimmune Pharmacol. 2010 Jun;5(2):176-88. doi: 10.1007/s11481-009-9181-3. Epub 2009 Nov 11. Review.

48.

Pathogenic MOG-reactive CD8+ T cells require MOG-reactive CD4+ T cells for sustained CNS inflammation during chronic EAE.

Bettini M, Rosenthal K, Evavold BD.

J Neuroimmunol. 2009 Aug 18;213(1-2):60-8. doi: 10.1016/j.jneuroim.2009.05.017. Epub 2009 Jun 21.

49.

Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity.

Manicassamy S, Ravindran R, Deng J, Oluoch H, Denning TL, Kasturi SP, Rosenthal KM, Evavold BD, Pulendran B.

Nat Med. 2009 Apr;15(4):401-9. doi: 10.1038/nm.1925. Epub 2009 Mar 1.

50.

CD8+ T cell responses to a viral escape mutant epitope: active suppression via altered SHP-1 activity.

Schnell FJ, Alberts-Grill N, Evavold BD.

J Immunol. 2009 Feb 15;182(4):1829-35. doi: 10.4049/jimmunol.0801798.

Supplemental Content

Loading ...
Support Center